Edition:
United States

Amgen Inc (AMGN.OQ)

AMGN.OQ on NASDAQ Stock Exchange Global Select Market

175.41USD
8 Dec 2017
Change (% chg)

$1.45 (+0.83%)
Prev Close
$173.96
Open
$174.43
Day's High
$175.95
Day's Low
$173.74
Volume
1,215,206
Avg. Vol
990,924
52-wk High
$191.08
52-wk Low
$138.83

Latest Key Developments (Source: Significant Developments)

Coherus Says Judge Issued Under Seal Report & Recommendation In Relation To Patent Infringement Complaint
Friday, 8 Dec 2017 01:11pm EST 

Dec 8 (Reuters) - Coherus Biosciences :COHERUS SAYS U.S. JUDGE RECOMMENDED COURT GRANT CO'S PENDING MOTION TO DISMISS AMGEN'S COMPLAINT FOR FAILURE TO STATE CLAIM .COHERUS BIOSCIENCES SAYS ON DEC 7, JUDGE ISSUED UNDER SEAL REPORT AND RECOMMENDATION TO DISTRICT COURT IN RELATION TO PATENT INFRINGEMENT COMPLAINT.COHERUS BIOSCIENCES SAYS CO EXPECTS DISTRICT COURT TO DECIDE IN Q1 2018 WHETHER TO ADOPT MAGISTRATE JUDGE'S RECOMMENDATION - SEC FILING.COHERUS BIOSCIENCES SAYS ‍REPORT AND RECOMMENDATION ISSUED BY JUDGE WITH RESPECT TO LITIGATION BETWEEN AMGEN, AMGEN MANUFACTURING LTD, CO​.  Full Article

Carmot Enters A Multi-Year Drug Discovery Collaboration With Amgen
Wednesday, 6 Dec 2017 07:00am EST 

Dec 6 (Reuters) - Amgen Inc ::CARMOT ENTERS A MULTI-YEAR DRUG DISCOVERY COLLABORATION WITH AMGEN.CARMOT THERAPEUTICS SAYS HAS ENTERED INTO A MULTI-YEAR DRUG DISCOVERY COLLABORATION AND LICENSING AGREEMENT WITH AMGEN.CARMOT THERAPEUTICS SAYS AS PART OF AGREEMENT, CARMOT AND AMGEN WILL WORK TOGETHER TO SELECT THERAPEUTIC TARGETS AND IDENTIFY DRUG CANDIDATES.CARMOT THERAPEUTICS SAYS UNDER AGREEMENT, AMGEN CAN SELECT MULTIPLE TARGETS TO PURSUE AND CARMOT WILL RECEIVE AN UPFRONT PAYMENT AND RESEARCH SUPPORT.CARMOT THERAPEUTICS SAYS IN ADDITION, CARMOT IS ELIGIBLE TO RECEIVE ROYALTIES ON NET SALES OF PRODUCTS RESULTING FROM COLLABORATION.  Full Article

Obsidian Therapeutics Announces $49.5 Mln Series A Financing To Develop Controllable Cell And Gene Therapy Products
Wednesday, 6 Dec 2017 06:15am EST 

Dec 6 (Reuters) - Takeda Pharmaceutical Co Ltd <4502.T>::OBSIDIAN THERAPEUTICS ANNOUNCES $49.5 MILLION SERIES A FINANCING TO DEVELOP CONTROLLABLE CELL AND GENE THERAPY PRODUCTS.OBSIDIAN THERAPEUTICS - SERIES A FINANCING LED BY GV, AND INCLUDED TAKEDA VENTURES, AMGEN VENTURES AMONG OTHERS.  Full Article

Biocartis And Amgen Sign Companion Diagnostic Agreement For Idylla(Tm) RAS Biomarker Tests
Monday, 4 Dec 2017 01:00am EST 

Dec 4 (Reuters) - BIOCARTIS GROUP NV ::BIOCARTIS AND AMGEN <<>> SIGN COMPANION DIAGNOSTIC AGREEMENT FOR IDYLLA(TM) RAS BIOMARKER TESTS.BIOCARTIS -WILL PURSUE A PREMARKET APPROVAL FOR IDYLLA KRAS MUTATION TEST AND IDYLLA NRAS-BRAF MUTATION TEST WITH FDA​.‍AMGEN WILL PROVIDE FINANCIAL AND OPERATIONAL SUPPORT TO BIOCARTIS FOR PMA PROCESS​.‍AIM OF AGREEMENT IS TO REGISTER IDYLLA RAS BIOMARKER TESTS WITH US FDA AS COMPANION DIAGNOSTIC TEST FOR AMGEN'S DRUG VECTIBIX(PANITUMUMAB).​.  Full Article

Amgen launches Enbrel Mini with Autotouch in U.S.
Friday, 17 Nov 2017 09:00am EST 

Nov 17 (Reuters) - Amgen Inc :Amgen launches the Enbrel Mini single-dose prefilled cartridge with autotouch reusable autoinjector that is ergonomically designed for patients.Enbrel Mini with autotouch is now available in United States​.  Full Article

Temasek Holdings takes share stake in Vantiv Inc, raises share stake in Amgen
Tuesday, 14 Nov 2017 07:13am EST 

Nov 14 (Reuters) - Temasek Holdings (Private) Ltd :Temasek Holdings (Private) Ltd takes share stake of 982,057 Class A shares in Vantiv Inc <<>> - SEC filing.Temasek Holdings (Private) Ltd raises share stake in Emerson Electric Co to 28,000 shares from 5,146 shares.Temasek Holdings (Private) Ltd raises share stake in Amgen Inc by about 25 percent to 188,527 shares.Temasek Holdings (Private) Ltd raises share stake in Biogen Inc by about 25 percent to 118,644 shares.Temasek Holdings (Private) Ltd - Change in holdings are as of Sept 30, 2017 and compared with the previous quarter ended as of June 30, 2017.Source text for quarter ended Sept 30, 2017 (http://bit.ly/2yBi2ic).Source text for quarter ended June 30, 2017: (http://bit.ly/2vUxgkf).  Full Article

Amgen receives positive CHMP opinion to expand use of Nplate in pediatric patients with chronic immune thrombocytopenic purpura
Friday, 10 Nov 2017 07:29am EST 

Nov 10 (Reuters) - Amgen Inc :Amgen receives positive CHMP opinion to expand use of Nplate® (romiplostim) in pediatric patients with chronic immune thrombocytopenic purpura.Amgen Inc - ‍positive CHMP opinion was based on five studies evaluating safety and efficacy of Nplate in children with ITP​, among other things.  Full Article

Amgen and Allergan receive positive chmp opinion for ABP 215
Friday, 10 Nov 2017 07:28am EST 

Nov 10 (Reuters) - Allergan Plc :Amgen and Allergan receive positive CHMP opinion for ABP 215 (biosimilar bevacizumab) for the treatment of certain types of cancer.Amgen Inc - ‍CHMP positive opinion will now be reviewed by European Commission, which has authority to approve medicines for European Union​.  Full Article

Amgen, Novartis announce expanded collaboration with Banner Alzheimer's Institute
Thursday, 2 Nov 2017 04:30pm EDT 

Nov 2 (Reuters) - Amgen Inc :Amgen and Novartis announce expanded collaboration with Banner Alzheimer's Institute in pioneering prevention program.Amgen - Co, ‍Novartis announced expanded collaboration with Banner Alzheimer's Institute to initiate new trial - API Generation Study 2​.  Full Article

‍Kirin-Amgen joint venture to become wholly-owned subsidiary of Amgen​
Tuesday, 31 Oct 2017 02:44am EDT 

Oct 31 (Reuters) - Amgen Inc :‍Kirin-Amgen joint venture to become wholly-owned subsidiary of Amgen​.‍Under terms of agreement, ‍Kirin-Amgen joint venture will pay $780 million to Kirin​.‍Kirin-Amgen will become a wholly-owned subsidiary of Amgen​.‍Joint venture ‍Kirin-Amgen will redeem Kirin's shares ​.‍Will make additional payments to Kirin upon occurrence of certain sales​.‍As sole shareholder of ‍Kirin-Amgen, Amgen will own product rights and remaining cash held by ‍Kirin-Amgen .‍License agreements between ‍Kirin-Amgen and KHK in certain Asian territories will remain in place​.  Full Article

BRIEF-Carmot Enters A Multi-Year Drug Discovery Collaboration With Amgen

* CARMOT ENTERS A MULTI-YEAR DRUG DISCOVERY COLLABORATION WITH AMGEN